Evidence map›Paper›PMID 31584979›Full record

ArticlePloS one2019

The investment case as a mechanism for addressing the NCD burden: Evaluating the NCD institutional context in Jamaica, and the return on investment of select interventions.

Brian Hutchinson, Roy Small, Kofi Acquah, Rosa Sandoval, Rachel Nugent, Tamu Davidson, Delia Itziar Belausteguigoitia, Nicholas Banatvala, Douglas Webb, Dudley Tarlton and 3 more

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Brian HutchinsonCenter for Noncommunicable Diseases, RTI International, Seattle, Washington, United States of America.ORCID 0000-0002-1576-5351
Roy SmallHIV, Health and Development Group, United Nations Development Programme, New York, New York, United States of America.
Kofi AcquahSocial Policy, Health and Economics Research (SPHERE), RTI International, Research Triangle Park, North Carolina, United States of America.
Rosa SandovalNoncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., United States of America.
Rachel NugentCenter for Noncommunicable Diseases, RTI International, Seattle, Washington, United States of America.
Tamu DavidsonNoncommunicable Diseases and Injuries Prevention, Jamaica Ministry of Health, Kingston, Jamaica
Delia Itziar BelausteguigoitiaNoncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., United States of America.
Nicholas BanatvalaUN Interagency Task Force on the Prevention and Control of Noncommunicable Diseases, World Health Organization, United Nations, Geneva, Switzerland.ORCID 0000-0001-8130-154X
Douglas WebbHIV, Health and Development Group, United Nations Development Programme, New York, New York, United States of America.
Dudley TarltonBureau Policy and Programme Support, United Nations Development Programme, New York, New York, United States of America.
Alexey KulikovUN Interagency Task Force on the Prevention and Control of Noncommunicable Diseases, World Health Organization, United Nations, Geneva, Switzerland.
Elisa PrietoNoncommunicable Diseases and Mental Health, Caribbean Subregional Program Coordination, Pan American Health Organization, Bridgetown, Barbados.
Karin SantiHIV, Health and Development Group, United Nations Development Programme, Panama City, Panama.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Noncommunicable diseases (NCDs) are a broad challenge for decision-makers. NCDs account for seven out of every 10 deaths globally, with 42 percent occurring prematurely in individuals under age 70. Despite their heavy toll, NCDs are underfunded, with only around two percent of global funding dedicated to the disease set. Country governments are responsible for funding targeted actions to reduce the NCD burden, but among other priorities, many have yet to invest in the health-system interventions and policy measures that can reduce the burden. This article examines "investment cases" as a potential mechanism for catalyzing attention to-and funding for-NCDs. In Jamaica, using the UN inter-agency OneHealth Tool, we conducted an economic analysis to estimate the return-on-investment from scaling up strategic clinical interventions, and from implementing or intensifying policy measures that target NCD risk factors. In addition, we conducted an institutional and context (ICA) analysis, interviewing stakeholders across sectors to take stock of promising policy pathways (e.g., areas of general consensus, political appetite and opportunity) as well as challenges to implementation. The economic analysis found that scaling up clinical interventions that target CVD, diabetes, and mental health disorders, and policy measures that target tobacco and alcohol use, would save over 6,600 lives between 2017-2032, and avert JMD 81.3 billion (USD 640 million) in direct and indirect economic costs that result from mortality and morbidity linked to NCDs. The ICA uncovered government economic growth targets and social priorities that would be aided by increased attention to NCDs, and it linked these targets and priorities to the economic analysis.

Identifiers

PMID31584979
PMCPMC6777795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.